ASTHMA DEGENERATIVE DISEASE

ASTHMA DEGENERATIVE DISEASE

Asthma is a common chronic inflammatory disease of the airways characterized by symptoms including wheezing, coughing, chest tightness, and shortness of breath, reversible airflow obstruction, and bronchospasm. Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate.[3] Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic). It can be exercised induced or occupational. Asthma affects an estimated 300 million people worldwide and caused 250,000 deaths in 2009. Traditional management usually focuses on reduction to allergen exposure and medical therapy that consists of beta-2-agonists, anti-cholinergics, or inhaled corticosteroids.  Asthma research has been ongoing around the world that exploits the anti-inflammatory and immuno-modulatory properties of adult stem cells to control the reactive airways associated with asthma. We are investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on chronic asthma. We use a protocol that includes a combination of intravenous and nebulized SVF delivery. Subjective reports, changes in steroid use and pulmonary function tests help measure outcomes in a meaningful way.  We care about our Asthma patients and take pride in the time we provide to our patients to deploy the best protocols to help our patients achieve their goals.

Brooklyn

2519 Avenue O
Brooklyn, NY 11210

Manhattan

200 Chambers Street
New York, NY 10007